AcouSort AB
AcouSort is an innovative technology company with high focus on products and solutions for automated preparation of biological samples for researchers and life science companies. The core technology is acoustofluidics where a combination of microfluidics and sound waves is used to separate blood into its components, to isolate and purify cells and extracellular vesicles and to perform rapid biochemical reactions. AcouSort’s core technology has been researched and developed for over 20 years at Lund University in the Department of Biomedical Engineering, research headed by Professor Thomas Laurell, board member of AcouSort.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Medical Equipment
- Market Focus:
- Globally (various continents)
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
About Us
The Early Diagnosis Challenge
Today, two out of three deaths are caused by either cancer, infections or cardiovascular diseases. In order to reduce the mortality in these key areas, early and accurate diagnosis is critical. Rapid diagnosis allows for quick medical interventions using the optimal treatment methods which drastically improves the outcome.
Improving healthcare is a multi-step process, starting with early research and identification of biomarkers. The knowledge gained in the research stage shall then be translated into diagnostic tools and subsequently, therapeutic treatments. AcouSort’s products has a unique ability to support this process throughout all stages.
Background
Over 20 Years of R&D at Lund University
AcouSort’s core technology has been researched and developed for over 20 years at Lund University in the Department of Biomedical Engineering, research headed by Professor Thomas Laurell. As the technology matured, its capabilities generated significant interest from life science companies.
In December 2010, AcouSort was founded in order to commercialize the research. The founders were professor Laurell together with three other Lund University professors: Hans Lilja (clinical chemistry), Patrik Brundin (neuroscience) and Stefan Scheding (hematology).
Initially, AcouSort’s activities were limited to conducting feasibility studies in collaboration with life-science companies. Eventually, the company developed its own benchtop instruments, AcouTrap and AcouWash, to facilitate research and application development.
In 2014, CEO Dr. Torsten Freltoft joined AcouSort, representing a strong commercial focus. He has led the development of the company’s current business strategy, focusing on developing OEM solutions for the healthcare market.
Strategy & Vision
AcouSort’s strategy is to use our innovative technology to revolutionize today’s healthcare. Its unique ability to automate and integrate sample processing steps will allow for a new generation of analytical and diagnostic devices. Patient samples can be analyzed directly at the point-of-care instead of at central laboratories, meaning the patient gets the results immediately. Through collaborations with leading life-science companies our technology will eliminate manual handling steps while saving time, money, and ultimately – lives.
Vision
Our vision is to improve healthcare impact and save lives across the globe by enabling more and better diagnostics, faster!
Mission
Our mission is to lead and drive the development and implementation of a new gold standard within clinical research, diagnostics and therapeutics by providing superior automated sample preparation solutions that radically change the way healthcare is provided today, removing the bottlenecks for tomorrows standard of care.
Main Goals
- Support new biomarker identification and diagnostic assay development for critically ill patients with high sense of urgency
- Enable significant growth of the point of care market across healthcare sectors
- Stay at the forefront of the acoustofluidics technology via in-house and collaborative R&D activities to support our vision
- Become the leading supplier of acoustofluidics sample preparation solutions for the healthcare market
Commercialization Strategy
Our commercialization strategy builds on our validated OEM business model offering sample preparation modules and solutions to providers of life science research instrumentation, diagnostic equipment and therapeutic systems
Quality
Our Quality Policy, based on our Mission is that:
- We shall ensure that our products always fulfill agreed customer requirements, and that they always provide safe and reliable output
- We shall maintain, and continuously improve, an effective and efficient Quality Management System that ensures that we fulfill customer and regulatory requirement
